Denali Therapeutics (DNLI) Receivables (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Receivables data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Receivables fell 5.88% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 5.88% decrease from a year earlier, with the FY2025 full-year figure at $2.2 million, changed 0.28% from the prior year.
• Receivables for Q1 2026 stood at $1.6 million, roughly flat from $1.6 million in the prior quarter.
• Over the last five years, Receivables for DNLI reached as high as $9.3 million in Q4 2022 and fell as low as $357000.0 in Q2 2022.
• Historically, Receivables has averaged $2.4 million across 5 years, with a median of $1.7 million in 2025.
• Across the five-year window, Receivables slumped 97.87% in 2022 and surged 852.38% in 2023, its largest moves.
• Year by year, Receivables stood at $9.3 million in 2022, then plunged by 70.91% to $2.7 million in 2023, then sank by 44.44% to $1.5 million in 2024, then grew by 6.67% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.